William Blair initiated coverage of Tenaya Therapeutics (NASDAQ:TNYA) with an outperform rating, citing its gene therapy candidate TN-201.
The investment firm believes TN-201 could reverse cardiac hypertrophy and provide durable improvements in cardiac function in patients with MYBPC3-associated hypertrophic cardiomyopathy.
William Blair also said it sees upcoming Phase 1 data for the product, expected in the second half of 2024, to provide “insight into TN-201’s therapeutic benefit and be a major catalyst for the stock.”
https://seekingalpha.com/news/4114530-william-blair-starts-tenaya-at-outperform-cites-upcoming-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.